 Oncophage is currently in clinical development for brain cancer, a devastating disease with few treatment options and survival rates of between three and six months, according to the lead investigator, Dr. Andrew Parsa from UCSF.The study is showing encouraging results and the first patient who received the vaccine, Ms Hammerman, was interviewed by "Good Morning America" describing her experiences of taking the vaccine.Elan 
While retaining his position at Antigenics, Armen became chairman of the board of directors for the biopharmaceutical company Élan Corporation plc from mid-2002 through 2004.